Literature DB >> 22564843

Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis.

Selma Tobudic1, Peter Matzneller, Brigitte Stoiser, Judith Maria Wenisch, Markus Zeitlinger, Andreas Vychytil, Walter Jaeger, Michaela Boehmdorfer, Gottfried Reznicek, Heinz Burgmann.   

Abstract

Blood and dialysate concentrations of fosfomycin were determined after intravenous and intraperitoneal application of 4 mg/liter in patients undergoing automated peritoneal dialysis. Maximum serum concentrations after intravenous (287.75 ± 86.34 mg/liter) and intraperitoneal (205.78 ± 66.78 mg/liter) administration were comparable. Ratios of intraperitoneal to systemic exposure were 1.12 (intraperitoneal administration) and 0.22 (intravenous administration), indicating good systemic exposure after intraperitoneal application but limited penetration of fosfomycin into the peritoneal fluid after the intravenous dose.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22564843      PMCID: PMC3393440          DOI: 10.1128/AAC.00126-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients.

Authors:  Chai Luan Low; Kamani Gopalakrishna; Wai Choong Lye
Journal:  J Am Soc Nephrol       Date:  2000-06       Impact factor: 10.121

2.  In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.

Authors:  F Tessier; C Quentin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-02       Impact factor: 3.267

3.  Pharmacokinetics of phosphonomycin in Man. I. Intravenous administration.

Authors:  K C Kwan; D A Wadke; E L Foltz
Journal:  J Pharm Sci       Date:  1971-05       Impact factor: 3.534

Review 4.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

5.  Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients.

Authors:  R J Elwell; H J Manley; R F Frye; G R Bailie
Journal:  Int J Artif Organs       Date:  2005-08       Impact factor: 1.595

6.  In vitro activity of fosfomycin in combination with various antistaphylococcal substances.

Authors:  K Grif; M P Dierich; K Pfaller; P A Miglioli; F Allerberger
Journal:  J Antimicrob Chemother       Date:  2001-08       Impact factor: 5.790

7.  Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing.

Authors:  D R Guay; W M Awni; C E Halstenson; M T Kenny; W F Keane; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

8.  Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis.

Authors:  Harold J Manley; George R Bailie; Reginald Frye; Lorraine D Hess; M Donald McGoldrick
Journal:  J Am Soc Nephrol       Date:  2000-07       Impact factor: 10.121

Review 9.  Long-term outcomes in automated peritoneal dialysis: similar or better than in continuous ambulatory peritoneal dialysis?

Authors:  Rajnish Mehrotra
Journal:  Perit Dial Int       Date:  2009-02       Impact factor: 1.756

10.  Changing patterns of peritoneal dialysis utilization in the United States.

Authors:  Rajnish Mehrotra
Journal:  Perit Dial Int       Date:  2007-06       Impact factor: 1.756

View more
  4 in total

1.  An Open, Randomized, Single-Center, Crossover Pharmacokinetic Study of Meropenem after Intraperitoneal and Intravenous Administration in Patients Receiving Automated Peritoneal Dialysis.

Authors:  Martin Wiesholzer; Petra Pichler; Gottfried Reznicek; Michaela Wimmer; Manuel Kussmann; Peter Balcke; Heinz Burgmann; Markus Zeitlinger; Wolfgang Poeppl
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 2.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

3.  Compatibility of fosfomycin with different commercial peritoneal dialysis solutions.

Authors:  M Kussmann; A Baumann; S Hauer; P Pichler; M Zeitlinger; M Wiesholzer; H Burgmann; W Poeppl; G Reznicek
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-07-06       Impact factor: 3.267

4.  Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa.

Authors:  Manuel Kussmann; Stefan Hauer; Petra Pichler; Gottfried Reznicek; Heinz Burgmann; Wolfgang Poeppl; Markus Zeitlinger; Martin Wiesholzer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-15       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.